From a series of eNewsletters

		Thank you for taking the time to discuss with me the benefi ts VERAMYST offers your patients. VERAMYST Nasal Spray is indicated for the treatment of symptoms of seasonal and perennial allergic rhinitis in patients ’†2 years old. VERAMYST has consistently proven to help relieve multiple allergy symptoms beyond congestion, it may be a treatment option for your patients. The grid below shares summarizes the data from 5 clinical studies in seasonal allergic rhinitis patients ’†12 years old.
		Superior Relief of Nasal Symptoms vs Allegra Comparable Relief of Ocular Symptoms vs Allegra
		RESULTS CONFIRMED IN A SECOND CLINICAL TRIAL. ’Ä° A secondary efficacy endpoint was the mean change from baseline over the entire 2-week treatment period in daily rTNSS. Baseline scores for VERAMYST, Allegra, and placebo, respectively, were 9.7, 9.8, and 9.8. Least square mean treatment difference between VERAMYST and Allegra was ’Äì0.9 (P<0.001); between VERAMYST and placebo, ’Äì1.2 (P<0.001); and between Allegra and placebo, ’Äì0.3 (P=0.136). ¬ßA secondary efficacy endpoint was the mean change from baseline over the entire 2-week treatment period in daily rTOSS. Baseline scores for VERAMYST, Allegra, and placebo, respectively, were 6.9, 6.9, and 7.0. Least square mean treatment difference between VERAMYST and Allegra was ’Äì0.3 (P=0.106); between VERAMYST and placebo, ’Äì0.5 (P=0.003); and between Allegra and placebo, ’Äì0.2 (P=0.286). ADVERSE REACTIONS IN HEAD-TO-HEAD STUDIES Overall adverse reactions were comparable to Allegra and placebo. Common adverse reactions with VERAMYST, Allegra, and placebo, respectively, included headache (4%, 3%-4%, 3%-4%), epistaxis (0%-2%, <1%-2%, <1%-2%), pharyngolaryngeal pain (1%-2%, <1%-1%, <1%-1%), and pyrexia (0%-<1%, 0%-1%, 0%-<1%).
		These data expand the body of evidence for VERAMYST supporting nasal and ocular symptom relief and safety. Please consider VERAMYST for your patients with seasonal and or perennial allergic rhinitis. Sincerely, Representative Pollen Representative for VERAMYST Please see the last page of this letter for Important Safety Information. Please consult accompanying complete Prescribing Information. Important Safety Information Overall adverse reactions were comparable to placebo. Common adverse reactions with VERAMYST vs placebo included headache (8%-9% vs 7%), epistaxis (4%-6% vs 4%), pharyngolaryngeal pain (2%-4% vs 1%-3%), nasal ulceration (1% vs <1%), back pain (1% vs <1%), pyrexia (4%-5% vs 2%), and cough (3%-4% vs 3%). Patients using VERAMYST over several months or longer should be examined periodically for evidence of Candida infection or other signs of adverse effects on the nasal mucosa. Patients who use corticosteroids are at risk for potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. A more serious or even fatal course of chickenpox or measles may occur in susceptible patients. Use caution in patients with the above because of the potential for worsening of these infections. When intranasal corticosteroids are used at higher than recommended dosages or at recommended dosages in susceptible individuals, hypercorticism and adrenal suppression may appear. Corticosteroids may cause a reduction in growth velocity in pediatric patients. Monitor growth routinely in pediatric patients receiving VERAMYST. Please consult accompanying complete Prescribing Information. References 1. Kaiser HB, Naclerio RM, Given J, Toler TN, Ellsworth A, Philpot EE. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;119(6):1430-1437. 2. Fokkens WJ, Jogi R, Reinartz S, et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy. 2007;62:1078-1084. 3. Data on file, GlaxoSmithKline. VMS0000